Quantcast

Latest Raloxifene Stories

2011-06-06 14:57:26

Buffalo enrolled more women than any other study site Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role. The findings will be published online June 4 at 11:30 a.m....

2011-05-06 08:52:00

BALTIMORE, May 6, 2011 /PRNewswire/ -- Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore. EVISTA-DVT focused on patients with blocked veins who had received clot-buster drug therapy (thrombolysis)....

2011-04-22 00:00:29

Recent research indicates medications such as Tamoxifen or Raloxifene considerably reduce the risk of developing breast cancer in post-menopausal women. MapleLeafMeds is a reputable source for quality drugs like Tamoxifen that doctors believe may slash the risk of breast cancer by up to 43%. Vancouver, BC (PRWEB) April 21, 2011 A recent article in the Lancet Oncology by a panel of cancer experts concluded that women in the higher risk categories for breast cancer could benefit from drugs...

2011-01-17 16:00:00

ROCKVILLE, Md., Jan. 17, 2011 /PRNewswire-USNewswire/ -- In an update to its 2002 recommendation, the U.S. Preventive Services Task Force (USPSTF) now recommends that all women ages 65 and older be routinely screened for osteoporosis. This is the first final recommendation statement to be published since the USPSTF implemented a new process in July 2010 in which all of its draft recommendation statements are posted for public comment on the USPSTF website prior to being issued in final...

2010-12-14 00:01:39

Results from an ongoing study examining two drugs to prevent breast cancer found that the drug raloxifene (Evista) was as almost effective as the standard drug tamoxifen (Nolvadex) and also produced fewer side effects. Earlier results of the study had shown that raloxifene was as effective as tamoxifen in reducing non-invasive breast cancer in post-menopausal women at high risk of developing the disease. For both drugs, women experienced a 50 percent reduction in breast cancer risk after 4...

2010-12-08 15:01:00

EMERYVILLE, Calif., Dec. 8, 2010 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that stimulate the production of or activate ERb are potential new therapies to prevent breast cancer. The study is entitled "Estrogen receptor beta causes a G2 cell cycle arrest by inhibiting CDK1...

2010-11-04 18:15:42

Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density, according to a study published online in The Journal of the National Cancer Institute. Lasofoxifene is a SERM, or selective estrogen receptor modulator, that, like tamoxifen, blocks the effects of estrogen in breast tissue. Another SERM, raloxifene, has been shown to reduce breast cancer risk. In the Postmenopausal Evaluation and...

2010-10-14 12:59:00

INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada. In partnership with TransPharma Medical Ltd.,...

2010-10-01 13:52:00

SEATTLE, Oct. 1 /PRNewswire/ -- Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship. The series launches today with "10 Tips for Breast Cancer Prevention"...

2010-09-30 07:00:00

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that three quarters of surveyed endocrinologists and rheumatologists who are aware of Amgen/GlaxoSmithKline's Prolia anticipate prescribing the drug. However, according to Treatment Algorithms in Osteoporosis, while awareness of Prolia is good among specialists (94 percent of surveyed endocrinologists and 85 percent of...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related